| Quarter (USD) | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 19.99 mm | 19.99 mm | 19.99 mm | 19.99 mm | 19.99 mm | 19.99 mm |
| Cash burn (monthly) | 455.33 k | 392.33 k | 3.85 mm | 4.17 mm | 3.54 mm | 3.52 mm |
| Cash used (since last report) | 1.18 mm | 1.02 mm | 9.95 mm | 10.79 mm | 9.17 mm | 9.12 mm |
| Cash remaining | 18.81 mm | 18.97 mm | 10.03 mm | 9.19 mm | 10.82 mm | 10.86 mm |
| Runway (months of cash) | 41.3 | 48.4 | 2.6 | 2.2 | 3.1 | 3.1 |
| 13F holders | Current |
|---|---|
| Total holders | 41 |
| Opened positions | 24 |
| Closed positions | 5 |
| Increased positions | 7 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 20.06 bn |
| Total shares | 25.37 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| BML Investment Partners | 5.75 mm | $6.73 mm |
| BML Capital Management | 5.75 mm | $7.93 bn |
| Adjuvant Global Health Technology Fund | 2.60 mm | $0.00 |
| Biotechnology Value Fund L P | 1.56 mm | $0.00 |
| Almitas Capital | 1.31 mm | $1.81 bn |
| Vanguard | 1.04 mm | $1.43 bn |
| Brii Biosciences | 927.20 k | $1.09 mm |
| PFE Pfizer | 715.30 k | $987.11 mm |
| Renaissance Technologies | 579.77 k | $800.09 mm |
| Peapod Lane Capital | 578.83 k | $798.78 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Jun 25 | Eric Easom | Common Stock | Buy | Acquire P | No | No | 1.0665 | 10,000 | 10.67 k | 256,380 |
| 30 May 25 | Braden Michael Leonard | Common Stock | Sell | Dispose S | Yes | No | 1.0324 | 7,000 | 7.23 k | 3,217,432 |
| 30 May 25 | Braden Michael Leonard | Common Stock | Sell | Dispose S | Yes | No | 1.01 | 425,000 | 429.25 k | 3,224,432 |
| 28 May 25 | Braden Michael Leonard | Common Stock | Sell | Dispose S | Yes | No | 1.09 | 200,000 | 218.00 k | 3,017,432 |
| 28 May 25 | Margaret M FitzPatrick | Common Stock | Buy | Acquire P | No | No | 1.1769 | 8,610 | 10.13 k | 8,610 |
| 28 May 25 | Braden Michael Leonard | Common Stock | Sell | Dispose S | Yes | No | 1.16 | 100,000 | 116.00 k | 3,649,432 |
| 28 May 25 | Braden Michael Leonard | Common Stock | Sell | Dispose S | Yes | No | 1.16 | 2,000,000 | 2.32 mm | 3,749,432 |
| 22 May 25 | Gilbert Lynn Marks | Stock Option Common Stock | Grant | Acquire A | No | No | 1.19 | 19,111 | 22.74 k | 19,111 |
